Arch Mal Coeur Vaiss
November 1989
Aging laboratory animals constantly present with chronic progressive nephrosis. The purpose of this study was to investigate the protective effect of a chronic treatment with cicletanine in aging rats, notably as regards kidneys. Sixteen Wistar rats aged 26 months were divided into two groups: one group served as control, while the other received oral cicletanine 30 mg/kg/day.
View Article and Find Full Text PDFIn order to demonstrate functional impairments related to hypertensive retinopathy, we experimented on the isolated retina of spontaneously hypertensive rats (SHR-SP strain A3N Iffa Credo). We also used this experimental model to assess the protective effect of treatment with cicletanine, a new synthetic furopyridine compound. Treatment consisted of daily oral administration of either 50 or 100 mg/kg of cicletanine for 5 weeks.
View Article and Find Full Text PDFAll studies carried out on stroke-prone spontaneously hypertensive rats (SHR-SP) have clearly demonstrated that cicletanine protects tissues and vessels. This effect has also been observed with captopril. However, the effectiveness of captopril seemed to be dependent on its blood pressure lowering effect, and this was not found with cicletanine in previous experimental studies on SHR-SP.
View Article and Find Full Text PDFParticularly rich in polyunsaturated fatty acids, the retina constitutes an excellent model for testing the functional consequences of membrane lipoperoxidation. The effects could be quantified by measuring the amplitude of the electroretinogram which represents the characteristic response of the retina to its physiological stimulus (light photons). The authors report results obtained on isolated rat retina maintained in survival by perfusion.
View Article and Find Full Text PDF